Hoth
Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b
Human Trial for Atopic Dermatitis Under Way
NEW YORK, NY
-- November 30, 2021 -- InvestorsHub NewsWire
-- Hoth Therapeutics, Inc.
(NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on
developing new generation therapies for unmet medical
needs, is pleased to announce that enrollment and dosing has begun for
the second cohort in its First in Human clinical trial
investigating topical BioLexa for the treatment of mild to moderate
atopic dermatitis, also known as
eczema.
"We are excited to have
reached this pivotal milestone in our BioLexa development program
to begin dosing adult patients," stated Stefanie Johns, Chief
Scientific Officer of Hoth Therapeutics. "The second cohort is
exclusively made up of current atopic dermatitis patients and we
look forward to sharing top of the line data in 2022."
Hoth is conducting
the
BioLexa clinical trial in Australia
Patient enrollment continues
for Phase 1. Anyone in Australia that is interested may review
trial requirements at
ClinicalTrials.Gov.
About BioLexa
BioLexa is a patented, proprietary
antimicrobial topical formulation being developed for treatment of
diseases mediated by Staphylococcal biofilms. Bacterial biofilms
are specialized communities consisting of bacteria adhered to a
surface (both biological and abiotic surfaces) and to other
bacteria, and often with a protective extracellular matrix. Mature
bacterial biofilms often result in chronic, recurrent infections
that are difficult to treat due to the barrier effect of the
biofilm that facilitates antibiotic resistance and avoiding immune
system mechanisms. The BioLexa formulation is optimized to prevent
Staphylococcal biofilm formation, keeping the bacteria in a more
susceptible state to antimicrobial therapy. This novel mechanism of
action has the potential to broadly treat clinical manifestations
resulting from Staphylococcal biofilm formation.
About Hoth Therapeutics,
Inc.
Hoth Therapeutics, Inc. is a
clinical-stage biopharmaceutical company focused on developing new
generation therapies for unmet medical needs. Hoth's pipeline
development is focused to improve the quality of life for patients
suffering from indications including atopic dermatitis, skin
toxicities associated with cancer therapy, chronic wounds,
psoriasis, asthma, acne, and pneumonia. Hoth has also entered into
two different agreements to further the development of two
therapeutic prospects to prevent or treat COVID-19. To learn more,
please visit www.hoththerapeutics.com.
Forward-Looking
Statement
This press release includes
forward-looking statements based upon Hoth's current expectations
which may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995 and other federal securities laws, and are
subject to substantial risks, uncertainties and assumptions. These
statements concern Hoth's business strategies; the timing of
regulatory submissions; the ability to obtain and maintain
regulatory approval of existing product candidates and any other
product candidates we may develop, and the labeling under any
approval we may obtain; the timing and costs of clinical trials,
the timing and costs of other expenses; market acceptance of our
products; the ultimate impact of the current Coronavirus pandemic,
or any other health epidemic, on our business, our clinical trials,
our research programs, healthcare systems or the global economy as
a whole; our intellectual property; our reliance on third party
organizations; our competitive position; our industry environment;
our anticipated financial and operating results, including
anticipated sources of revenues; our assumptions regarding the size
of the available market, benefits of our products, product pricing,
timing of product launches; management's expectation with respect
to future acquisitions; statements regarding our goals, intentions,
plans and expectations, including the introduction of new products
and markets; and our cash needs and financing plans. There are a
number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
You should not place reliance on these forward-looking statements,
which include words such as "could," "believe," "anticipate,"
"intend," "estimate," "expect," "may," "continue," "predict,"
"potential," "project" or similar terms, variations of such terms
or the negative of those terms. Although the Company believes that
the expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section entitled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Contact
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678)
570-6791